U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07047885) titled 'Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)' on June 23.
Brief Summary: This is a single-center, phase I/IB study to identify the recommended phase II dose of Ropeginterferon-alfa 2b (P1101) in patients with CTCL who have failed at least two prior lines of skin-directed therapy (Stage IA-IB) or have less than a complete response to phototherapy or extracorporeal photopheresis (ECP) or total skin electron beam therapy (TSET), or stable/progressive disease after at least two lines of topical therapy (Stage IIA-IIIB).
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Cutaneous T Cell Lymphoma
Int...